Cargando…

Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis

Excessive decreases in bone volume (BV) and bone mineral density (BMD) can lead to osteoporosis, potentially hindering implant osseointegration. Bisphosphonates are commonly used to combat osteoporosis by slowing osteoclast‐mediated resorption; however, functional osteoclasts are integral to bone re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotz, Ethan M., Cohen, David J., Ellis, Regan A., Wayne, Jennifer S., Schwartz, Zvi, Boyan, Barbara D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659452/
https://www.ncbi.nlm.nih.gov/pubmed/31372590
http://dx.doi.org/10.1002/jbm4.10184
_version_ 1783439135642484736
author Lotz, Ethan M.
Cohen, David J.
Ellis, Regan A.
Wayne, Jennifer S.
Schwartz, Zvi
Boyan, Barbara D.
author_facet Lotz, Ethan M.
Cohen, David J.
Ellis, Regan A.
Wayne, Jennifer S.
Schwartz, Zvi
Boyan, Barbara D.
author_sort Lotz, Ethan M.
collection PubMed
description Excessive decreases in bone volume (BV) and bone mineral density (BMD) can lead to osteoporosis, potentially hindering implant osseointegration. Bisphosphonates are commonly used to combat osteoporosis by slowing osteoclast‐mediated resorption; however, functional osteoclasts are integral to bone remodeling and, thus, implant osseointegration, potentially contraindicating bisphosphonate use during implantation. To optimize the use of implant technologies in patients with compromised bone structure and metabolism, we need a more complete understanding of the biological response to surface design. The goal of this study was to assess the effects of osteoporosis and bisphosphonates on osseointegration of titanium (Ti) implants with microstructured surfaces, which have been shown to support osteoblast differentiation in vitro and rapid osseointegration in vivo. Forty, 8‐month‐old, virgin, female CD Sprague Dawley rats underwent ovariectomy (OVX) or sham (SHOVX) surgery. After 5 weeks, animals were injected subcutaneously with either the bisphosphonate (BIS), Ibandronate (25 µg/kg), or phosphate‐buffered saline (PBS) every 25 days. 1 week after the initial injection, Ø2.5mm × 3.5mm microrough (SLA; grit‐blasted/acid etched) implants were placed transcortically in the distal metaphysis of each femur resulting in four groups: 1) SHOVX+PBS; 2) SHOVX+BIS; 3) OVX+PBS; and 4) OVX+BIS. After 28d, qualitative properties of the bone and implant osseointegration were assessed using micro‐computed tomography (microCT), calcified histomorphometry (Van Gieson's stain), and removal torque testing. microCT revealed decreased bone volume in OVX rats, which was slowed by bisphosphonate treatment. Reduced bone‐to‐implant contact (BIC) was evident in OVX+PBS compared to SHOVX+PBS. Although BV/TV was increased in OVX+BIS compared to OVX+PBS, bisphosphonate treatment had no effect on BIC. Removal torque testing revealed a higher maximum torque, torsional stiffness, and torsional energy in SHOVX compared to OVX with no effects due to bisphosphonate treatment. Our results show that osseointegration is decreased in osteoporotic animals. Ibandronate halts the progression of osteoporosis but does not enhance osseointegration. © 2019 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research
format Online
Article
Text
id pubmed-6659452
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66594522019-08-01 Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis Lotz, Ethan M. Cohen, David J. Ellis, Regan A. Wayne, Jennifer S. Schwartz, Zvi Boyan, Barbara D. JBMR Plus Original Articles Excessive decreases in bone volume (BV) and bone mineral density (BMD) can lead to osteoporosis, potentially hindering implant osseointegration. Bisphosphonates are commonly used to combat osteoporosis by slowing osteoclast‐mediated resorption; however, functional osteoclasts are integral to bone remodeling and, thus, implant osseointegration, potentially contraindicating bisphosphonate use during implantation. To optimize the use of implant technologies in patients with compromised bone structure and metabolism, we need a more complete understanding of the biological response to surface design. The goal of this study was to assess the effects of osteoporosis and bisphosphonates on osseointegration of titanium (Ti) implants with microstructured surfaces, which have been shown to support osteoblast differentiation in vitro and rapid osseointegration in vivo. Forty, 8‐month‐old, virgin, female CD Sprague Dawley rats underwent ovariectomy (OVX) or sham (SHOVX) surgery. After 5 weeks, animals were injected subcutaneously with either the bisphosphonate (BIS), Ibandronate (25 µg/kg), or phosphate‐buffered saline (PBS) every 25 days. 1 week after the initial injection, Ø2.5mm × 3.5mm microrough (SLA; grit‐blasted/acid etched) implants were placed transcortically in the distal metaphysis of each femur resulting in four groups: 1) SHOVX+PBS; 2) SHOVX+BIS; 3) OVX+PBS; and 4) OVX+BIS. After 28d, qualitative properties of the bone and implant osseointegration were assessed using micro‐computed tomography (microCT), calcified histomorphometry (Van Gieson's stain), and removal torque testing. microCT revealed decreased bone volume in OVX rats, which was slowed by bisphosphonate treatment. Reduced bone‐to‐implant contact (BIC) was evident in OVX+PBS compared to SHOVX+PBS. Although BV/TV was increased in OVX+BIS compared to OVX+PBS, bisphosphonate treatment had no effect on BIC. Removal torque testing revealed a higher maximum torque, torsional stiffness, and torsional energy in SHOVX compared to OVX with no effects due to bisphosphonate treatment. Our results show that osseointegration is decreased in osteoporotic animals. Ibandronate halts the progression of osteoporosis but does not enhance osseointegration. © 2019 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research John Wiley and Sons Inc. 2019-03-06 /pmc/articles/PMC6659452/ /pubmed/31372590 http://dx.doi.org/10.1002/jbm4.10184 Text en © 2019 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lotz, Ethan M.
Cohen, David J.
Ellis, Regan A.
Wayne, Jennifer S.
Schwartz, Zvi
Boyan, Barbara D.
Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
title Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
title_full Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
title_fullStr Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
title_full_unstemmed Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
title_short Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
title_sort ibandronate treatment before and after implant insertion impairs osseointegration in aged rats with ovariectomy induced osteoporosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659452/
https://www.ncbi.nlm.nih.gov/pubmed/31372590
http://dx.doi.org/10.1002/jbm4.10184
work_keys_str_mv AT lotzethanm ibandronatetreatmentbeforeandafterimplantinsertionimpairsosseointegrationinagedratswithovariectomyinducedosteoporosis
AT cohendavidj ibandronatetreatmentbeforeandafterimplantinsertionimpairsosseointegrationinagedratswithovariectomyinducedosteoporosis
AT ellisregana ibandronatetreatmentbeforeandafterimplantinsertionimpairsosseointegrationinagedratswithovariectomyinducedosteoporosis
AT waynejennifers ibandronatetreatmentbeforeandafterimplantinsertionimpairsosseointegrationinagedratswithovariectomyinducedosteoporosis
AT schwartzzvi ibandronatetreatmentbeforeandafterimplantinsertionimpairsosseointegrationinagedratswithovariectomyinducedosteoporosis
AT boyanbarbarad ibandronatetreatmentbeforeandafterimplantinsertionimpairsosseointegrationinagedratswithovariectomyinducedosteoporosis